In studying the late health effects of atomic-bomb (A-bomb) survivors, earlier findings were that white blood cell (WBC) count increased with radiation dose in cross-sectional studies. However, a persistent effect of radiation on WBC count and other risk factors has yet to be confirmed. The objectives of the present study were 1) to examine the longitudinal relationship between A-bomb radiation dose and WBC and differential WBC counts among A-bomb survivors and 2) to investigate the potential confounding risk factors (such as age at exposure and smoking status) as well as modification of the radiation dose-response. A total of 7,562 A-bomb survivors in Hiroshima and Nagasaki were included in this study from 1964-2004. A linear mixed model was applied using the repeated WBC measurements. During the study period, a secular downward trend of WBC count was observed. Radiation exposure was a significant risk factor for elevated WBC and differential WBC counts over time. A significant increase of WBC counts among survivors with high radiation dose (> 2 Gy) was detected in men exposed below the age of 20 and in women regardless of age at exposure. Effects on WBC of low dose radiation remain unclear, however. Cigarette smoking produced the most pronounced effect on WBC counts and its impact was much larger than that of radiation exposure.

Download full-text PDF

Source
http://dx.doi.org/10.1269/jrr.09081DOI Listing

Publication Analysis

Top Keywords

wbc counts
16
white blood
12
blood cell
12
a-bomb survivors
12
wbc count
12
radiation dose
12
wbc
11
radiation
8
risk factors
8
wbc differential
8

Similar Publications

Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. However, the relationship between the PLR and prognosis in myeloma patients has not been clearly demonstrated.

View Article and Find Full Text PDF

Therapy-related acute myeloid leukemia (t-AML), which develops after cytotoxic therapy, has a poorer prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential cure, its efficacy varies among patients. In this retrospective study, we analyzed 154 patients with t-AML who underwent hematopoietic stem cell transplantation (HSCT) at our institution to determine their clinical characteristics and develop a prognostic nomogram.

View Article and Find Full Text PDF

Objective: To obtain standard reference values of intraocular pressure measured with rebound tonometry in conscious healthy Egyptian vultures (Neophron percnopterus).

Methods: 17 Egyptian vultures presented for a routine health check, involving a full physical examination, blood film examination, Hct, manual total leukocyte count, and plasma biochemistry. 15 animals considered healthy and with no signs of stress underwent an ophthalmic examination, including observation of facial symmetry, adnexa, and direct fundoscopy to screen for ocular disease.

View Article and Find Full Text PDF

Objective: In patients with primary hypertension (PH), left ventricular hypertrophy (LVH) is a critical predictor of cardiovascular events. We aimed to identify clinical and laboratory predictors of LVH in patients with PH.

Methods: This retrospective cohort study included 2321 patients with PH at the Fifth Affiliated Hospital of Xinjiang Medical University from December 2022 to January 2024.

View Article and Find Full Text PDF

Risk Factors Predicting Outcomes in Advanced Upper Gastrointestinal Cancers Treated With Immune Checkpoint Inhibitors.

Gastroenterology Res

December 2024

Division of Medical Oncology, Department of Internal Medicine, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.

Background: Immune checkpoint inhibitors (ICIs) have moved to the frontline in recent years to manage upper gastrointestinal (UGI) tumors, such as esophageal and gastric cancers. This retrospective review sheds light on real-world data on ICI-treated UGI tumors to identify risk factors (clinical and pathological) impacting the outcome other than traditional biomarkers (programmed cell death ligand 1 (PD-L1) or microsatellite instability status).

Methods: Patients with UGI tumors who received at least one dose of ICI for stage IV or recurrent disease between January 1, 2015, and July 31, 2021, at The Ohio State University were included in the study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!